Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial
来那度胺联合利妥昔单抗（R(2)）治疗既往未接受治疗的边缘区淋巴瘤：一项开放标签 II 期试验的亚组分析和长期随访
期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.15843
Becnel, Melody R; Nastoupil, Loretta J; Samaniego, Felipe; Davis, Richard E; You, M J; Green, Michael; Hagemeister, Fredrick B; Fanale, Michelle A; Fayad, Luis E; Westin, Jason R; Wang, Michael; Oki, Yasuhiro; Forbes, Sheryl G; Feng, Lei; Neelapu, Sattva S; Fowler, Nathan H
